Clinical Trial

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Protocol Amendment History 2 changes
notable Trial sites expanded: 52 -> 55 locations 2026-05-14
notable Trial sites expanded: 49 -> 52 locations 2026-04-14
Trial Details
NCT Number NCT06979596
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm
Enrollment 250 participants
Start Date 2025-08-11
Primary Completion 2027-11-04 (estimated)
Study Completion 2027-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-17